Healthcare Review: Amarin Corporation, Pluristem Therapeutics, Agenus, Sequenom, ISIS Pharmaceuticals Are Notable Movers Print E-mail
By Staff and Wire Reports   
Friday, 09 November 2012 15:03
Stocks advanced on Friday, but were well off session highs after comments by President Barack Obama and House of Representatives Speaker John Boehner left investors little hope that a deal to avoid the "fiscal cliff" was on the horizon.

Both the S&P 500 and the Nasdaq had risen 1 percent around midday following economic data showing consumer sentiment was at its highest level in more than five years and wholesale inventories jumped in September.

Amarin Corporation plc (ADR) (NASDAQ:AMRN)
stock gained 7.61% to $11.03 after the company reported a third-quarter GAAP net loss of $26.4 million, or $0.18 per share, as compared to net income of $96.3 million, or $0.62 per share in the year ago quarter. Analysts expected the company to report a loss of $0.22 per share for the quarter. Non-GAAP adjusted net loss was $39.4 million or $0.26 per share. The company did not generate revenue for the both latest and prior year quarter.

Pluristem Therapeutics Inc. (NASDAQ:PSTI)
shares increased 8.39% to $3.09. The company offered comments on an article published in Bloomberg on November 7, 2012. Pluristem has submitted a direct request to Bloomberg to publish a correction because the article it published is factually inaccurate and misleading.

The company has requested that the news agency issue a correction specific to the article's claim and implication that Pluristem knew of the death of this patient at the time of a recent capital raising transaction and withheld this information from its investors. A morning report contradicted Bloomberg and pointed out that Pluristem management and did not learn of these facts until after the financing was completed.

Agenus Inc. (NASDAQ:AGEN)
stock climbed 5.18% to $4.47 after the company announced the second complete set of results from the Phase 3 trial of GlaxoSmithKline's RTS,S malaria vaccine candidate (also known as Mosquirix), which contains Agenus' QS-21 Stimulon adjuvant. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S.

Sequenom, Inc. (NASDAQ:SQNM)
shares climbed 20.46% to $3.65 in the early hour after the company reported a third quarter net loss of $0.26 per share, as compared to the loss of $0.19 per share last year. Revenues came in at $22.9 million, up from $13.6 million in the previous year.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
stock surged 16.17% to $8.89 after the company reported a pro forma net operating loss (NOL) of $26.0 million and $36.0 million for the three and nine months ended September 30, 2012, respectively, compared to a pro forma NOL of $20.0 million and $44.9 million for the same periods in 2011. The Company ended the third quarter of 2012 with $343.6 million in cash.

Additionally, Cowen upgraded shares of ISIS from a neutral rating to an outperform rating in a research report released today.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter